You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Rivastigmine tartrate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for rivastigmine tartrate and what is the scope of patent protection?

Rivastigmine tartrate is the generic ingredient in two branded drugs marketed by Novartis, Alembic Pharms Ltd, Apotex Inc, Aurobindo Pharma, Cadila Pharms Ltd, Chartwell Rx, Dr Reddys Labs Inc, Macleods Pharms Ltd, Orbion Pharms, Sun Pharm, and Watson Labs, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.

There are fifteen drug master file entries for rivastigmine tartrate. Thirteen suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for rivastigmine tartrate
Drug Prices for rivastigmine tartrate

See drug prices for rivastigmine tartrate

Recent Clinical Trials for rivastigmine tartrate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.Phase 1/Phase 2
Duke UniversityPhase 1/Phase 2
Taishoff Family FoundationPhase 1/Phase 2

See all rivastigmine tartrate clinical trials

Generic filers with tentative approvals for RIVASTIGMINE TARTRATE
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign Up2MG/MLSOLUTION; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for rivastigmine tartrate
Anatomical Therapeutic Chemical (ATC) Classes for rivastigmine tartrate
Paragraph IV (Patent) Challenges for RIVASTIGMINE TARTRATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
EXELON Oral Solution rivastigmine tartrate 2 mg/mL 021025 1 2004-11-05
EXELON Capsules rivastigmine tartrate 1.5 mg, 3 mg, 4.5 mg and 6 mg 020823 3 2004-04-21

US Patents and Regulatory Information for rivastigmine tartrate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Inc RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 091072-002 May 16, 2013 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Watson Labs RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 077129-003 Jan 8, 2008 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Watson Labs RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 077129-002 Jan 8, 2008 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Apotex Inc RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 091072-001 May 16, 2013 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Watson Labs RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 077129-004 Jan 8, 2008 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for rivastigmine tartrate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-003 Apr 21, 2000 ⤷  Sign Up ⤷  Sign Up
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-004 Apr 21, 2000 ⤷  Sign Up ⤷  Sign Up
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-005 Apr 21, 2000 ⤷  Sign Up ⤷  Sign Up
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-006 Apr 21, 2000 ⤷  Sign Up ⤷  Sign Up
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-006 Apr 21, 2000 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.